<DOC>
	<DOCNO>NCT02096380</DOCNO>
	<brief_summary>Two Phase Ⅲ trial ( TAX323 TAX324 ) show induction chemotherapy add docetaxel cisplatin plus fluorouracil ( TPF ) could significant improve survival head neck cancer , Phase Ⅱ trial Hong Kong Hui college strategy also report nasopharyngeal carcinoma ( NPC ) . However , whether three cycle induction could delay whole time treatment reduce survival benefit still unknown . A retrospective study one cycle TPF induction chemotherapy investigator group ( yet publish ) could improve survival NPC . It encourage u conduct clinical trial .</brief_summary>
	<brief_title>The Value Single-cycle TPF Induction Chemotherapy Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Patients present non-keratinizing NPC stage Ⅲ-Ⅳb T3-4N1M0/TxN2M0 randomly assign receive one cycle induction chemotherapy ( docetaxel+cisplatin+fluorouracil ) plus concurrent chemoradiotherapy ( investigational arm ) three cycle induction chemotherapy ( docetaxel+cisplatin+fluorouracil ) plus concurrent chemoradiotherapy ( investigational arm ) ( control arm ) . Patients arm receive radical Intensity modulate radiation therapy ( Trilogy , Varian ) , cisplatin ( 30mg/m2 ) every week six cycle radiotherapy . Radiation deliver GTV 70 Gy 30 fraction , CTV1 60 Gy 30 fraction CTV2 54 Gy 30 fraction . Patients investigational arm receive docetaxel ( 60mg/m2 day 1 ) , cisplatin ( 20mg/m2 day 1-4 ) fluorouracil ( 800mg/m2/d , continuous infusion , day 1-4 ) every three week one cycle three cycle radiotherapy . The primary end point response rate radiotherapy , failure-free survival ( FFS ) toxic effect treatment compliance . Secondary end point include overall survival ( OS ) , distant failure-free survival ( D-FFS ) , locoregional failure-free survival ( LR-FFS ) . All efficacy analysis conduct intention-to-treat population ; safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing ( accord World Health Organization ( WHO 2005 ) histologically type ) . Satisfactory performance status : Karnofsky scale ( KPS ) &gt; 70 . Tumor stag accord 7th American Joint Commission Cancer edition Stage III：T12N2M0 , T3N02M0 Stage IVa：T4N02M0 Adequate marrow : leucocyte count ≥4000/μL , hemoglobin ≥90g/L platelet count ≥100000/μL . Normal liver function test : Alanine Aminotransferase ( ALT ) 、Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤2.5×ULN , bilirubin ≤ULN . Adequate renal function : creatinine clearance ≥60 ml/min . Age &gt; 60 year &lt; 18 year . Pregnancy lactation . Treatment palliative intent . Prior radiotherapy , chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease include unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>cycle</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>docetaxel</keyword>
</DOC>